Softwr

Research · head to head

DNAnexus vs LatchBio

DNAnexus logo

DNAnexus

Research

Regulated cloud platform for genomic and multiomic data, with GxP and FedRAMP coverage

From
On request
Rated
-
Full reviewWebsite
LatchBio logo

LatchBio

AI

AI agents that run bioinformatics analyses, from a company that pivoted from workflow hosting

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: DNAnexus no pricing is published, so an organisation cannot compare the total cost against running the same pipelines on its own cloud account until it is deep in a sales process.; LatchBio the company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • They diverge on capability: DNAnexus covers Governed data storage, LatchBio covers Agent driven analysis.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which DNAnexus and LatchBio actually diverge.

Attributes where DNAnexus and LatchBio differ
AttributeDNAnexusLatchBio
PlatformsWeb, LinuxWeb
CategoryResearchAI

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in DNAnexus

  • Governed data storage
  • Workflow execution
  • App building
  • Controlled collaboration
  • Compliance posture
  • Cohort browsing

Only in LatchBio

  • Agent driven analysis
  • Multi assay support
  • Published benchmarks
  • White labelled portals
  • Common file format handling
  • Managed compute

What people use each for

The jobs each tool is most often brought in to do.

DNAnexus

  • A clinical diagnostics laboratory that needs a CLIA and CAP aligned environment for production sequencing pipelines without building the compliance evidence itselfnot LatchBio
  • A pharma sponsor analysing genomic endpoints in a registrational programme where 21 CFR Part 11 records are requirednot LatchBio
  • A biobank or consortium giving hundreds of external researchers governed access to a dataset too large to distributenot LatchBio
  • A diagnostics vendor packaging its pipeline as a versioned app so partner laboratories can run it without receiving the source codenot LatchBio

LatchBio

  • A small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quicklynot DNAnexus
  • An assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw filesnot DNAnexus
  • A wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facilitynot DNAnexus
  • A research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegatednot DNAnexus

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

DNAnexus

  • No pricing is published, so an organisation cannot compare the total cost against running the same pipelines on its own cloud account until it is deep in a sales process.
  • Compute and storage are billed through the platform rather than at underlying cloud list price, so the compliance envelope carries a persistent margin on every terabyte and core hour, which grows with the science rather than staying fixed.
  • Data egress at genomic scale is slow and chargeable, so leaving the platform later is a real project rather than a contract decision, and that gravity weakens negotiating position at renewal.
  • The regulated and validated configurations sit in a higher commercial tier than the research configuration, so an organisation that starts in research mode and later needs GxP faces a repricing rather than a setting change.
  • Bioinformaticians used to running Nextflow on their own infrastructure find the platform abstractions constraining, and porting an existing pipeline into the app model is engineering work that does not carry over to any other platform.

LatchBio

  • The company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • Agent generated analysis code has to be validated by someone who could have written it, which inverts the value proposition for the small labs that most need it and cannot check the output.
  • No pricing is published, so the cost of routine agent analysis at team scale cannot be estimated without contacting sales, and compute billed through the platform makes the bill usage dependent.
  • Regulated use is a poor fit: an agent that writes non deterministic analysis code is difficult to validate under GxP, so this is a research tool rather than something that will sit in a regulated diagnostic or submission workflow.
  • The vendor publishes its own benchmarks, which is more than most competitors do, but self reported benchmarks on selected datasets are not a substitute for testing the agent on your own data before committing.

Pricing, plan by plan

DNAnexus

On request
  • DNAnexus Platform$undefined/year
    • Quoted per organisation through a sales process
    • Storage and compute billed through the platform rather than at cloud list price
    • Regulated and validated configurations are a separate commercial tier

LatchBio

On request
  • LatchBio Platform$undefined/year
    • Quoted through a sales process
    • Interactive sandbox available for trying the agent before contracting
    • Enterprise and white labelled portal deployments priced separately

Which should you pick?

Choose DNAnexus if

  • You need governed data storage.
  • You work on Web, Linux.
  • You also want workflow execution.
DNAnexus review

Choose LatchBio if

  • You need agent driven analysis.
  • You also want multi assay support.
LatchBio review

Questions people ask

Is DNAnexus or LatchBio better?
Neither clearly leads. DNAnexus starts at On request and LatchBio at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, DNAnexus or LatchBio?
DNAnexus starts at On request and LatchBio at On request.
Does DNAnexus or LatchBio run on more platforms?
DNAnexus runs on Web, Linux. LatchBio runs on Web.
What is DNAnexus best used for?
DNAnexus is most often used for a clinical diagnostics laboratory that needs a clia and cap aligned environment for production sequencing pipelines without building the compliance evidence itself, a pharma sponsor analysing genomic endpoints in a registrational programme where 21 cfr part 11 records are required, a biobank or consortium giving hundreds of external researchers governed access to a dataset too large to distribute, a diagnostics vendor packaging its pipeline as a versioned app so partner laboratories can run it without receiving the source code. Of those, a clinical diagnostics laboratory that needs a clia and cap aligned environment for production sequencing pipelines without building the compliance evidence itself and a pharma sponsor analysing genomic endpoints in a registrational programme where 21 cfr part 11 records are required are not what LatchBio is typically brought in for.
What can DNAnexus do that LatchBio cannot?
DNAnexus covers Governed data storage, Workflow execution, App building, Controlled collaboration. LatchBio covers Agent driven analysis, Multi assay support, Published benchmarks, White labelled portals.

Answered from the vendors’ own pages

DNAnexus: Why pay for DNAnexus instead of raw AWS?

For the compliance evidence. GxP, FedRAMP, CLIA, CAP and Part 11 coverage removes a validation programme most organisations would otherwise have to build and maintain themselves.

LatchBio: Is LatchBio still selling the original workflow platform?

The company is now led by agent.bio and its agent products. Buyers evaluating the older Python SDK workflow platform should confirm current support directly.

DNAnexus: Is validated use included?

No. Regulated and validated configurations sit in a separate commercial tier from ordinary research use.

LatchBio: Can I try it before buying?

Yes. There is an interactive sandbox where you can upload data and run the agent before entering a sales conversation.

DNAnexus: Can I get my data out?

Yes, but egress at genomic scale is chargeable and slow, so plan exit costs at the point of signing.

LatchBio: Is it suitable for regulated work?

Not really. Non deterministic agent generated code is hard to validate under GxP, so treat it as a research and exploration tool.

DNAnexus: Does it host UK Biobank?

Yes, DNAnexus hosts the UK Biobank research analysis platform, which has its own access approval and cost terms.

LatchBio: What data types does it handle?

Single cell RNA sequencing, spatial transcriptomics, epigenomics, proteomics and pharmacology data, ingesting FastQ, H5AD and spreadsheet formats.

Share

Related pages

More on DNAnexus

More on LatchBio

Keep looking

Other head to heads